Imprimis Pharmaceuticals Company Profile (NASDAQ:IMMY)

About Imprimis Pharmaceuticals

Imprimis Pharmaceuticals logoImprimis Pharmaceuticals, Inc. (Imprimis) is engaged in the development, production and dispensing of compounded pharmaceuticals. The Company operates through the business of developing drug therapies and providing such therapies through sterile and non-sterile pharmaceutical compounding services segment. The Company, through its Imprimis Cares program, owns, markets and dispenses a portfolio of compounded therapeutic in several therapeutic areas, including ophthalmology, urology, otolaryngology and infectious diseases. The Company is also developing Custom Compounding Choice business, which is focused on developing and dispensing a portfolio of non-proprietary compounded drugs for humans and animals in therapeutic areas that may be overlooked by commercial pharmaceutical companies. The Company also offers customizable compounding products that consist of sterile injectable and non-sterile integrative medicine therapies that are used in various therapeutic areas.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: IMMY
  • CUSIP:
Key Metrics:
  • Previous Close: $3.76
  • 50 Day Moving Average: $3.96
  • 200 Day Moving Average: $3.92
  • 52-Week Range: $3.34 - $8.79
  • Trailing P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $49.56M
  • Outstanding Shares: 13,180,000
  • Beta: -0.32
Profitability:
  • Net Margins: -117.69%
  • Return on Equity: -477.98%
  • Return on Assets: -95.23%
Debt:
  • Debt-to-Equity Ratio: 1.68%
  • Current Ratio: 1.77%
  • Quick Ratio: 1.50%
Additional Links:
Companies Related to Imprimis Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Imprimis Pharmaceuticals (NASDAQ:IMMY) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Imprimis Pharmaceuticals (NASDAQ:IMMY)
Show:
DateFirmActionRatingPrice TargetDetails
7/23/2015Sterne Agee CRTInitiated CoverageBuy$10.00View Rating Details
12/18/2014CRT CapitalInitiated CoverageBuy$13.00View Rating Details
12/16/2014Craig HallumInitiated CoverageBuy$12.00View Rating Details
(Data available from 9/27/2014 forward)

Earnings

Earnings History for Imprimis Pharmaceuticals (NASDAQ:IMMY)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/10/2016        
8/15/2016Q216($0.35)$4.53 million$4.90 millionViewListenView Earnings Details
5/12/2016Q116($0.27)($0.43)$3.24 million$4.40 millionViewListenView Earnings Details
3/23/2016Q415($0.26)($0.31)$3.52 million$3.50 millionViewListenView Earnings Details
11/12/2015Q3($0.38)($0.25)ViewListenView Earnings Details
8/12/2015Q215($0.33)($0.39)$2.13 million$2.00 millionViewListenView Earnings Details
5/13/2015Q115($0.25)($0.33)$1.55 million$16.00 millionViewN/AView Earnings Details
3/12/2015Q414($0.25)($0.30)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Imprimis Pharmaceuticals (NASDAQ:IMMY)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Imprimis Pharmaceuticals (NASDAQ:IMMY)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Imprimis Pharmaceuticals (NASDAQ:IMMY)
Insider Ownership Percentage: 14.59%
Institutional Ownership Percentage: 24.94%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/11/2016Opaleye Management Inc.Major ShareholderBuy45,000$3.65$164,250.00View SEC Filing  
6/30/2015Opaleye Management Inc.Major ShareholderBuy35,000$7.90$276,500.00View SEC Filing  
5/19/2015Donald Paul MiloniMajor ShareholderSell410,000$8.00$3,280,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Imprimis Pharmaceuticals (NASDAQ:IMMY)
DateHeadline
biz.yahoo.com logoIMPRIMIS PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers (NASDAQ:IMMY)
biz.yahoo.com - September 26 at 5:43 PM
biz.yahoo.com logoIMPRIMIS PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers (NASDAQ:IMMY)
biz.yahoo.com - September 26 at 5:43 PM
4-traders.com logoImprimis Pharmaceuticals : Pharma`s CEO Publishes Drug Pricing Monograph (NASDAQ:IMMY)
www.4-traders.com - September 23 at 5:17 PM
finance.yahoo.com logoFollowing Congressional Hearing Investigating Mylan and Epi-Pen, Imprimis Pharmaceuticals Founder and CEO Publishes Drug Pricing Monograph (NASDAQ:IMMY)
finance.yahoo.com - September 22 at 8:47 AM
biz.yahoo.com logoIMPRIMIS PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events (NASDAQ:IMMY)
biz.yahoo.com - September 14 at 9:50 AM
News IconCorporate Document-Fact Sheet - Q2 2016 for Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY)
www.companyspotlight.com - September 7 at 9:01 AM
finance.yahoo.com logoImprimis Pharmaceuticals Launches Imprimis Cares Access Network (ICAN) to Assist in Patient Access to Imprimis Cares® Compounded Formulations (NASDAQ:IMMY)
finance.yahoo.com - September 6 at 10:22 AM
finance.yahoo.com logoIMPRIMIS PHARMACEUTICALS, INC. Financials (NASDAQ:IMMY)
finance.yahoo.com - August 24 at 5:30 PM
benzinga.com logoBenzinga Talks With Imprimis Pharmaceuticals' CEO About Earnings, MKO Melt, Drug Pricing And More (NASDAQ:IMMY)
www.benzinga.com - August 22 at 10:13 AM
sg.finance.yahoo.com logoImprimis reports 2Q loss (NASDAQ:IMMY)
sg.finance.yahoo.com - August 15 at 8:47 PM
biz.yahoo.com logoQ2 2016 Imprimis Pharmaceuticals Inc Earnings Release - After Market Close (NASDAQ:IMMY)
biz.yahoo.com - August 15 at 3:16 PM
finance.yahoo.com logoImprimis Pharmaceuticals Strengthens Senior Leadership Team with Key Hires in Operations, Quality, Manufacturing and Client Relations (NASDAQ:IMMY)
finance.yahoo.com - August 15 at 3:16 PM
finance.yahoo.com logoInvestor Calendar Invites You to the Imprimis Pharmaceuticals Second Quarter 2016 Earnings Conference Call and Webcast Live on Monday, August 15, 2016 (NASDAQ:IMMY)
finance.yahoo.com - August 15 at 3:16 PM
biz.yahoo.com logoIMPRIMIS PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion of Acquisit (NASDAQ:IMMY)
biz.yahoo.com - August 11 at 5:53 PM
finance.yahoo.com logoMedical Product Stock Earnings Coming Up: IMMY, OMCM, CLRB (NASDAQ:IMMY)
finance.yahoo.com - August 11 at 8:38 AM
finance.yahoo.com logoImprimis Pharmaceuticals Announces $2 Million Equipment Sale Leaseback Agreement with Essex Capital Corporation (NASDAQ:IMMY)
finance.yahoo.com - August 11 at 8:38 AM
finance.yahoo.com logoImprimis Pharmaceuticals to Host its Second Quarter 2016 Financial Report Conference Call and Webcast … (NASDAQ:IMMY)
finance.yahoo.com - August 1 at 10:22 AM
finance.yahoo.com logoImprimis Pharmaceuticals to Host its Second Quarter 2016 Financial Report Conference Call and Webcast on August 15, 2016 at 4:30 p.m. EDT (NASDAQ:IMMY)
finance.yahoo.com - August 1 at 9:00 AM
4-traders.com logoImprimis Launches New MaxRx Prescriber Portal(TM) (NASDAQ:IMMY)
www.4-traders.com - July 30 at 5:09 PM
News IconImprimis announces availability of new MaxRx Prescriber Portal (NASDAQ:IMMY)
www.news-medical.net - July 30 at 5:09 PM
News IconImprimis Launches New MaxRx Prescriber Portal (NASDAQ:IMMY)
www.itbusinessnet.com - July 29 at 5:48 PM
finance.yahoo.com logoImprimis Launches New MaxRx Prescriber Portal™ (NASDAQ:IMMY)
finance.yahoo.com - July 29 at 9:00 AM
4-traders.com logoImprimis Pharmaceuticals : Peer-Reviewed Study of Dropless Cataract Surgery Shows `Measurable Benefits` Compared to Drops (NASDAQ:IMMY)
www.4-traders.com - July 23 at 5:21 PM
finance.yahoo.com logo9:02 am Imprimis Pharmaceuticals announces results of a clinical study comparing the efficacy of its injected triamcinolone acetonide, moxifloxacin hydrochloride and vancomycin Dropless Therapy formulation to drops commonly prescribed after (NASDAQ:IMMY)
finance.yahoo.com - July 22 at 9:02 AM
finance.yahoo.com logoPeer-Reviewed Study of Dropless Cataract Surgery Shows 'Measurable Benefits' Compared to Drops (NASDAQ:IMMY)
finance.yahoo.com - July 22 at 9:00 AM
capitalcube.com logoETF’s with exposure to Imprimis Pharmaceuticals, Inc. : July 19, 2016 (NASDAQ:IMMY)
www.capitalcube.com - July 19 at 12:35 PM
biz.yahoo.com logoIMPRIMIS PHARMACEUTICALS, INC. Files SEC form 8-K, Termination of a Material Definitive Agreement (NASDAQ:IMMY)
biz.yahoo.com - June 17 at 5:26 PM
biz.yahoo.com logoIMPRIMIS PHARMACEUTICALS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders (NASDAQ:IMMY)
biz.yahoo.com - June 15 at 6:08 AM
finance.yahoo.com logoImprimis Pharmaceuticals to Present at 6th Annual LD Micro Invitational on June 8, 2016 (NASDAQ:IMMY)
finance.yahoo.com - June 3 at 8:30 AM
benzinga.com logoExclusive: Meet One Pharma CEO Who's Doing Something To Bring Down Drug Prices (NASDAQ:IMMY)
www.benzinga.com - June 1 at 5:58 PM
capitalcube.com logoImprimis Pharmaceuticals, Inc. :IMMY-US: Earnings Analysis: Q1, 2016 By the Numbers : June 1, 2016 (NASDAQ:IMMY)
www.capitalcube.com - June 1 at 12:25 PM
finance.yahoo.com logoImprimis Pharmaceuticals to Present at the Jefferies 2016 Healthcare Conference (NASDAQ:IMMY)
finance.yahoo.com - June 1 at 8:30 AM
sg.finance.yahoo.com logoImprimis reports 1Q loss (NASDAQ:IMMY)
sg.finance.yahoo.com - May 12 at 4:31 PM
finance.yahoo.com logoImprimis Pharmaceuticals Announces First Quarter 2016 Financial Results and Provides Business Update (NASDAQ:IMMY)
finance.yahoo.com - May 12 at 4:05 PM
biz.yahoo.com logoIMPRIMIS PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition (NASDAQ:IMMY)
biz.yahoo.com - May 12 at 4:03 PM
finance.yahoo.com logoClinical Study of Imprimis Pharmaceuticals' Tri-Moxi-Vanc Dropless Therapy Formulation Show Statistically Significant Reduction in Cystoid Macular Edema in Patients Following Cataract Surgery (NASDAQ:IMMY)
finance.yahoo.com - May 12 at 8:30 AM
biz.yahoo.com logoQ1 2016 Imprimis Pharmaceuticals Inc Earnings Release - After Market Close (NASDAQ:IMMY)
biz.yahoo.com - May 12 at 7:07 AM
finance.yahoo.com logoInvestor Calendar Invites You to the Imprimis Pharmaceuticals First Quarter 2016 Earnings Conference Call and Webcast Live on Thursday, May 12, 2016 (NASDAQ:IMMY)
finance.yahoo.com - May 11 at 4:25 PM
finance.yahoo.com logoImprimis Pharmaceuticals Announces Plans to Launch IV Free™ Conscious Sedation and New Compounded Triple Drop Formulations at Leading Cataract and Refractive Surgeons Meeting (NASDAQ:IMMY)
finance.yahoo.com - May 5 at 8:30 AM
finance.yahoo.com logoImprimis Pharmaceuticals to Host its First Quarter 2016 Financial Report Conference Call and Webcast on May 12, 2016 at 4:30 p.m. EDT (NASDAQ:IMMY)
finance.yahoo.com - May 4 at 8:30 AM
finance.yahoo.com logoImprimis Pharmaceuticals Begins Dispensing Lower Cost Alternative to Thiola® (NASDAQ:IMMY)
finance.yahoo.com - May 2 at 8:30 AM
biz.yahoo.com logoIMPRIMIS PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements an (NASDAQ:IMMY)
biz.yahoo.com - April 26 at 5:02 PM
finance.yahoo.com logoImprimis Pharmaceuticals Registers its Texas Facility with the FDA as an Outsourcing Facility (NASDAQ:IMMY)
finance.yahoo.com - April 12 at 7:30 AM
finance.yahoo.com logoEdited Transcript of IMMY earnings conference call or presentation 23-Mar-16 8:30pm GMT (NASDAQ:IMMY)
finance.yahoo.com - April 11 at 5:22 PM
capitalcube.com logoETF’s with exposure to Imprimis Pharmaceuticals, Inc. : April 5, 2016 (NASDAQ:IMMY)
www.capitalcube.com - April 5 at 5:26 PM
finance.yahoo.com logoImprimis Pharmaceuticals to Make a Lower Cost Compounded and Customizable Alternative to Thiola® (NASDAQ:IMMY)
finance.yahoo.com - February 10 at 9:00 AM
forbes.com logoCall Martin Shkreli Whatever You Want, But Not A Pharma CEO - Forbes (NASDAQ:IMMY)
www.forbes.com - February 7 at 2:50 PM
News IconVideo-Rising Cost of Drugs for Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY)
www.companyspotlight.com - February 4 at 5:43 PM
finance.yahoo.com logoImprimis Pharmaceuticals, Inc. (IMMY) (NASDAQ:IMMY)
finance.yahoo.com - February 3 at 2:47 PM
News IconLatest Analysts Reports On Imprimis Pharmaceuticals, Inc. (IMMY) - Risers & Fallers (NASDAQ:IMMY)
www.risersandfallers.com - January 28 at 2:37 PM

Social

Imprimis Pharmaceuticals (NASDAQ:IMMY) Chart for Tuesday, September, 27, 2016


Last Updated on 9/27/2016 by MarketBeat.com Staff